ArticleLipids in health and disease2025
Association between myosteatosis or sarcopenia based on abdominal CT and hypertension in systemic lupus erythematosus patients.
Article in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association between the CRP-TyG index and lupus nephritis risk.Biomolecules & biomedicine · 2025Article
- Correction: Association between myosteatosis or sarcopenia based on abdominal CT and hypertension in systemic lupus erythematosus patients.Lipids in health and disease · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertension and obesity are common in systemic lupus erythematosus (SLE) patients, with obesity-related changes potentially driving hypertension. However, the specific adiposity measures associated with hypertension in SLE patients remain unclear. This study assessed the association between myosteatosis and sarcopenia detected on abdominal CT and hypertension in SLE patients. Mediators of the association between myosteatosis and hypertension were also investigated.
methodsThis was a retrospective study involving SLE patients enrolled from January 2017 to August 2023 and who underwent abdominal CT at the L3 level to track myosteatosis and sarcopenia based on the skeletal muscle mean radiodensity (SMD) and skeletal muscle index considered as binary and continuous variables. The association between these body composition measures and hypertension was tested using logistic regression analyses, while mediation modeling was used to assess the mediators.
resultsA total of 279 adult SLE patients (median age, 41.00 [30.00, 51.00] years; 245 women) were included in this study. Hypertension was associated with myosteatosis (adjusted OR: 3.54; 95% CI: 1.18-10.61 for the binary variable and 1.31; 95% CI: 1.02-1.68 for the continuous variable). No statistically significant association was observed between hypertension and sarcopenia (adjusted OR: 0.48; 95%CI: 0.23-1.01 for the binary variable and 0.95; 95%CI: 0.78-1.16 for the continuous variable). Mediation analyses revealed eGFR could mediate the association between myosteatosis (considered as a continuous variable) and hypertension in SLE patients when taken alone (95% CI: 0.0177-0.2765) or in combination with the TyG index (95% CI: 0.0032-0.0614).
conclusionsMyosteatosis was associated with hypertension in SLE patients. eGFR alone or in combination with the TyG index may mediate this association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.